VKTX Share Price Performance
US$28.75
1.79 (6.64%)
69.0% undervalued intrinsic discount
US$92.72
Fair Value
Price US$28.75
AnalystConsensusTarget US$92.72
AnalystHighTarget US$125.00
Fair ValueUS$92.72
Share Pricen/a
Seeking Alpha • Jun 10
Viking Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 167 Fair Values set on narratives written by author
VKTX Community Narratives
AN
Fair Value
·Fair Value US$92.72 69.0% undervalued intrinsic discount
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$125 77.0% undervalued intrinsic discount
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
Catalysts About Viking Therapeutics Viking Therapeutics focuses on developing therapies for obesity and related cardiometabolic conditions, with VK2735 as its lead dual GLP-1 and GIP receptor agonist program in both injectable and oral forms. What are the underlying business or industry changes driving this perspective?Read more
AN
US$125
77.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
310.37x
Price in 2029
US$0
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Catalysts About Viking Therapeutics Viking Therapeutics is a clinical stage biopharmaceutical company focused on therapies for obesity and related metabolic disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
US$92.72
69.0% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
1.11kx
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
Fair Value: US$125 77.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Fair Value: US$92.72 69.0% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Viking Therapeutics, Inc. Key Details
About VKTX
- Founded
- 2012
- Employees
- 59
- CEO
- WebsiteView website
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
